Genome&Company US Subsidiary ListBio Raises $31 Million Investment
[Asia Economy Reporter Lee Seon-ae] Genome & Company, a specialized immuno-oncology company, announced on the 31st that its U.S. subsidiary List Biotherapeutics (hereinafter List Bio) has secured $31 million in Series A funding.
The investment will be used to build a microbiome pharmaceutical contract development and manufacturing organization (CDMO) plant in Fishers, Indiana, USA.
Genome & Company established List Bio in October this year and announced the plant construction plan in November.
The investment involved eight parties, including Korea Investment Partners, Korea Investment & Securities, and DSC Investment. List Bio plans to receive additional Series A funding in the first quarter of next year.
Hot Picks Today
600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division: "Three Paychecks Under One Roof"
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Penalty Surcharges to Exceed Illicit Gains for Hoarding... Government Announces Strong Response to Market Disruption
- "Disappointing Results: 80% of Sunscreens Found Lacking in Safety and Effectiveness"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
CEO Bae Ji-soo said, "Genome & Company's entry into the CDMO business is significant in creating a virtuous cycle structure that secures stable sales and enables bold investment in new drug research and development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
